{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:10:23Z","timestamp":1787065823937,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.humpath.2024.105649","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T12:51:45Z","timestamp":1724331105000},"page":"105649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Therapeutic indications for antibody-drug conjugates estimated from HER2 and p53 expressions in endometrial carcinoma"],"prefix":"10.1016","volume":"152","author":[{"given":"Junya","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4436-838X","authenticated-orcid":false,"given":"Mitsutake","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumika","family":"Zaitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yabuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2024.105649_bib1","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2024.105649_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2024.105649_bib3","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2024.105649_bib4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41379-019-0220-1","article-title":"Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma","volume":"32","author":"Yano","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2024.105649_bib5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2024.105649_bib6","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized Phase II Trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in Uterine serous Carcinomas that overexpress Human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.105649_bib7","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized Phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III\u2013IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2024.105649_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2024.105649_bib9","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.22.00575","article-title":"Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a Phase II Trial","volume":"41","author":"Yamaguchi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.105649_bib10","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.105649_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010044","article-title":"HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes","volume":"13","author":"Vermij","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.humpath.2024.105649_bib12","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","article-title":"Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas","volume":"35","author":"Ross","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2024.105649_bib13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.humpath.2023.04.009","article-title":"Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma","volume":"137","author":"Sukov","year":"2023","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2024.105649_bib14","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/modpathol.3800171","article-title":"Prognostic significance of HER2\/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung","volume":"17","author":"Saad","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2024.105649_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/hupa.2002.30183","article-title":"Prognostic value of immunohistochemical expressions of p53, HER-2\/neu, and bcl-2 in stage I non-small-cell lung cancer","volume":"33","author":"Han","year":"2002","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2024.105649_bib16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4103\/1947-2714.183013","article-title":"Coexistence of HER2, Ki67, and p53 in osteosarcoma: a strong prognostic factor","volume":"8","author":"Mardanpour","year":"2016","journal-title":"N Am J Med Sci"},{"key":"10.1016\/j.humpath.2024.105649_bib17","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/bcr738","article-title":"Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer","volume":"6","author":"Yamashita","year":"2004","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.humpath.2024.105649_bib18","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.105649_bib19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American pathologists, American society for clinical Pathology, and American society of clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2024.105649_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","volume":"40","author":"Buza","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.humpath.2024.105649_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100299","article-title":"HER2 genetic intratumor heterogeneity is associated with resistance to trastuzumab and trastuzumab Emtansine therapy in recurrent high-grade endometrial cancer","volume":"36","author":"Shen","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2024.105649_bib22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated molecular characterization of uterine carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2024.105649_bib23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41420-020-00337-4","article-title":"Attenuation of p53 mutant as an approach for treatment Her2-positive cancer","volume":"6","author":"Fedorova","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.humpath.2024.105649_bib24","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.annonc.2023.08.005","article-title":"HER2-low expression in patients with advanced or metastatic solid tumors","volume":"34","author":"Uzunparmak","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2024.105649_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2024.01.048","article-title":"Human epidermal growth factor receptor-2 (HER2) expression in FIGO 3 high-grade endometrial endometrioid carcinoma: clinicopathologic characteristics and future directions","volume":"185","author":"Abada","year":"2024","journal-title":"Gynecol Oncol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724001588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724001588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T22:35:30Z","timestamp":1727130930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817724001588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":25,"alternative-id":["S0046817724001588"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2024.105649","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic indications for antibody-drug conjugates estimated from HER2 and p53 expressions in endometrial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2024.105649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105649"}}